US 11,731,952 B2
Indene derivatives and uses thereof
Nathan G. Dolloff, Mt. Pleasant, SC (US); Reeder M. Robinson, Charleston, SC (US); Allen B. Reitz, Lansdale, PA (US); and Haiyan Bian, Princeton, NJ (US)
Assigned to MUSC Foundation for Research Development, Charleston, SC (US); and Lukogene Therapeutics Incorporated, Mt. Pleasant, SC (US)
Appl. No. 16/633,464
Filed by MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, Charleston, SC (US); and LEUKOGENE THERAPEUTICS INCORPORATED, Mt. Pleasant, SC (US)
PCT Filed Aug. 29, 2018, PCT No. PCT/US2018/048449
§ 371(c)(1), (2) Date Jan. 23, 2020,
PCT Pub. No. WO2019/046368, PCT Pub. Date Mar. 7, 2019.
Claims priority of provisional application 62/552,449, filed on Aug. 31, 2017.
Prior Publication US 2020/0165182 A1, May 28, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 39/38 (2006.01); C07C 43/225 (2006.01); C07C 61/29 (2006.01); C07C 69/708 (2006.01); C07C 233/02 (2006.01); C07C 233/58 (2006.01); C07D 317/70 (2006.01); C07D 317/52 (2006.01); C07D 319/14 (2006.01); C07D 263/52 (2006.01); C07C 69/712 (2006.01); A61P 35/00 (2006.01); C07C 62/32 (2006.01); C07C 69/757 (2006.01); C07C 235/40 (2006.01); C07C 235/34 (2006.01); C07C 49/255 (2006.01); C07C 59/72 (2006.01); C07C 65/11 (2006.01)
CPC C07D 317/70 (2013.01) [A61P 35/00 (2018.01); C07C 39/38 (2013.01); C07C 43/225 (2013.01); C07C 49/255 (2013.01); C07C 59/72 (2013.01); C07C 61/29 (2013.01); C07C 62/32 (2013.01); C07C 65/11 (2013.01); C07C 69/708 (2013.01); C07C 69/712 (2013.01); C07C 69/757 (2013.01); C07C 233/02 (2013.01); C07C 233/58 (2013.01); C07C 235/34 (2013.01); C07C 235/40 (2013.01); C07D 263/52 (2013.01); C07D 317/52 (2013.01); C07D 319/14 (2013.01); C07C 2601/14 (2017.05); C07C 2602/08 (2017.05)] 15 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
one of R1 or R2 is hydroxyl, and the other is hydroxyl, alkyl, alkoxy, methoxy-acetate, phosphate, valine, Gly-Ser, —OC(O)CH2OC(O)CH3, —OC(O)CH2OCH3, —OCH2C(O)C(CH3)3, —OCH2C(O)NH2 or —OCH2C(O)OH; or R1 and R2, together with the carbon atoms to which they are attached, form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen;
R3 is —CF3; and
R4 is alkenyl, said alkenyl optionally mono or bi-substituted independently with hydrogen, halogen, hydroxyl, —OCH2-phenyl, cycloalkyl, —OCH2-halophenyl or —OCH2-phenylhaloalkyl,
or a pharmaceutically acceptable salt thereof.